Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.

ABSTRACT:

Importance

It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast cancer.

Objective

To investigate whether low ERBB2 expression is associated with distinct clinicopathologic characteristics and prognosis among patients with hormone receptor (HR)-positive and triple-negative breast cancer (TNBC).

Design, setting, and participants

This cohort study was conducted using data from a prospectively maintained institutional database on all consecutive patients with breast cancer undergoing surgery between January 2016 and March 2021 at Dana-Farber Brigham Cancer Center. The study included 5235 patients with stage I through III, ERBB2-negative invasive breast cancer. Tumors were classified as ERBB2-low if

SUBMITTER: Tarantino P 

PROVIDER: S-EPMC9227690 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature